$AMED, $BAX, $JNJ
Daily HeffX-LTN reviews dozens of Wall Street’s Key analysts research reports to ID new trading and investing ideas for HeffX-LTN readers. Some reports cover stocks to buy, and others cover stocks to sell or avoid.
Below is our list for Monday, 4 May, as follows:
Amedisys: AMED is a leading health care stock is a pure-play on an aging nation. Amedisys Inc (NASDAQ:AMED) provides healthcare services in the United States.
It operates through 3 segments, as follows:
The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability or terminal illness, as well as prevents avoidable hospital readmission through its skilled nurses; rehabilitation therapists specialized in physical, speech and occupational therapy; and social workers and aides for assisting its patients.
The Hospice segment offers services that are designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer’s or cancer.
The Personal Care segment provides assistance for patients with the activities of daily living.
As of 18 February 2020, the company owned and operated 479 care centers in 38 states and the District of Columbia.
We are Very Bullish long term, our target price is 225 for the shares, the Wall Street consensus target is 211.46. Amedisys stock closed Friday at 189.83.
Baxter International: BAX is another health care play, this is solid stock to own, especially with hospitals and doctors ready to restart non-C-19 related procedures. Baxter International Inc. (NYSE:BAX) provides a portfolio of renal and hospital products. Its Renal segment provides products and services to treat end-stage renal disease, irreversible kidney failure and acute kidney therapies. This segment offers a comprehensive portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis, in-center hemodialysis (HD), home HD, continuous renal replacement therapy and additional dialysis services.
Baxter’s Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation and packaging technologies.
Shareholders receive a 0.97% dividend. We agree with the Street’s consensus target at 105.25. Baxter stock closed at 87.84 Friday.
Johnson & Johnson: JNJ has a diverse product base and a very popular and solid brand, this is among the most conservative big pharmaceutical plays. Johnson & Johnson (NYSE:JNJ) is 1 of the Top market cap stocks in the healthcare sector and will raise the dividend for shareholders this year for the 57th yr running.
With everything from medical devices to OTC health items and Rx drugs, Johnson & Johnson is 1 of the most diversified health care names on Wall Street. It is also among the Top companies helping Americans to fight the C-19 coronavirus.
The healthcare giant also has one of the most exciting pipelines of new drugs in the sector. That combined with the solid over-the-counter product business makes the stock an outstanding holding for conservative accounts with a long-term investment outlook. The company generates a little over half of its sales in international markets, which are expected to see higher spending on health care over the next 10 yrs and beyond.
The dividend recently was raised to 1.01/share from 0.95, or a 2.67% yield. JNJ has mad a V recovery and a break of the Key resistance at 151.59 augurs a run to 200, the stock closed Friday at 148.29.
Have healthy week, Keep the Faith!
Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.